Explore

Trendline Trendline
Actio Biosciences Initiates Trial for KCNT1-Related Epilepsy Treatment

Actio Biosciences Initiates Trial for KCNT1-Related Epilepsy Treatment

Actio Biosciences Initiates Trial for KCNT1-Related Epilepsy Treatment
Trendline Trendline
Harbour BioMed Receives FDA Clearance for New Cancer Treatment Trial

Harbour BioMed Receives FDA Clearance for New Cancer Treatment Trial

Harbour BioMed Receives FDA Clearance for New Cancer Treatment Trial
Trendline Trendline
Vistagen Completes Phase 3 Study for Fasedienol in Social Anxiety Disorder

Vistagen Completes Phase 3 Study for Fasedienol in Social Anxiety Disorder

Vistagen Completes Phase 3 Study for Fasedienol in Social Anxiety Disorder
Trendline Trendline
Rocket Pharmaceuticals Advances Gene Therapy Pipeline with FDA Engagement and Financial Strength

Rocket Pharmaceuticals Advances Gene Therapy Pipeline with FDA Engagement and Financial Strength

Rocket Pharmaceuticals Advances Gene Therapy Pipeline with FDA Engagement and Financial Strength
Trendline Trendline
Rznomics Secures FDA RMAT Designation for RZ-001 in Hepatocellular Carcinoma Treatment

Rznomics Secures FDA RMAT Designation for RZ-001 in Hepatocellular Carcinoma Treatment

Rznomics Secures FDA RMAT Designation for RZ-001 in Hepatocellular Carcinoma Treatment
Trendline Trendline
Stoke Therapeutics Reports Positive Data on Zorevunersen for Dravet Syndrome

Stoke Therapeutics Reports Positive Data on Zorevunersen for Dravet Syndrome

Stoke Therapeutics Reports Positive Data on Zorevunersen for Dravet Syndrome
Trendline Trendline
FDA to Reconsider Rejection of Ebvallo Cell Therapy for Rare Disease

FDA to Reconsider Rejection of Ebvallo Cell Therapy for Rare Disease

FDA to Reconsider Rejection of Ebvallo Cell Therapy for Rare Disease
Trendline Trendline
Pierre Fabre Pharmaceuticals Aligns with FDA for Tabelecleucel Resubmission to Treat Rare Lymphoma

Pierre Fabre Pharmaceuticals Aligns with FDA for Tabelecleucel Resubmission to Treat Rare Lymphoma

Pierre Fabre Pharmaceuticals Aligns with FDA for Tabelecleucel Resubmission to Treat Rare Lymphoma
Trendline Trendline
Intellia Therapeutics Advances CRISPR Gene Editing with FDA Application for Hereditary Angioedema Treatment

Intellia Therapeutics Advances CRISPR Gene Editing with FDA Application for Hereditary Angioedema Treatment

Intellia Therapeutics Advances CRISPR Gene Editing with FDA Application for Hereditary Angioedema Treatment
Trendline Trendline
Harbour BioMed Receives FDA Clearance for HBM7004 to Treat Advanced Solid Tumors

Harbour BioMed Receives FDA Clearance for HBM7004 to Treat Advanced Solid Tumors

Harbour BioMed Receives FDA Clearance for HBM7004 to Treat Advanced Solid Tumors
Trendline Trendline
Amylyx Pharmaceuticals Advances Avexitide for Post-Bariatric Hypoglycemia with Phase 3 Trial Completion

Amylyx Pharmaceuticals Advances Avexitide for Post-Bariatric Hypoglycemia with Phase 3 Trial Completion

Amylyx Pharmaceuticals Advances Avexitide for Post-Bariatric Hypoglycemia with Phase 3 Trial Completion
Trendline Trendline
FDA Reverses Stance on Atara and Pierre Fabre's Cell Therapy Following Leadership Change

FDA Reverses Stance on Atara and Pierre Fabre's Cell Therapy Following Leadership Change

FDA Reverses Stance on Atara and Pierre Fabre's Cell Therapy Following Leadership Change